{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:59:19Z","timestamp":1771477159750,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To determine whether universal masking during COVID-19 altered rate and outcomes of postinjection endophthalmitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective, single-site, comparative, cohort study. Eyes diagnosed with endophthalmitis within 4 weeks of intravitreal injection at the University of Michigan from August 1, 2012, to November 15, 2022, were identified. Cases were considered \u201cmasking\u201d between March 15, 2020, and November 15, 2022. Endophthalmitis rate, visual acuity, and microbial spectrum were investigated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>There were 20 postinjection endophthalmitis cases out of 72,194 injections (0.028%; one in 3,571 injections) premasking and 10 of 38,962 with universal masking (0.026%; one in 3,846 injections; odds ratio 0.9; 95% [confidence interval]: 0.4\u20132.0). Referral from the community was unchanged with 32 cases referred premasking (0.35 cases\/month) and 10 cases with masking (0.31 cases\/month). Presenting mean the logarithm of the minimum angle of resolution visual acuity with masking of all postinjection endophthalmitis cases trended worse (2.35 \u00b1 0.40) compared with premasking (2.09 \u00b1 0.48; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.05) with light perception visual acuity more common with masking (31.6% vs. 10.9%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.06). There was no delay in time from procedure to initial treatment (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.36), no difference in the rate of initial treatment with tap and inject (T\/I), and similar positive-culture rates (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.77) between the cohorts. Visual acuity after 30 days of follow-up was clinically unchanged (\u223c20\/500 vs. 20\/400; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.59).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Universal masking had no effect on postinjection endophthalmitis rate or on the rate of culture-positive cases. Although presenting visual acuity appeared worse with masking, this was not statistically significant, and current treatment paradigms resulted in similar visual outcomes.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000004043","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T21:00:50Z","timestamp":1705006850000},"page":"916-922","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["NO EFFECT OF REAL-WORLD UNIVERSAL FACE MASKING ON POST-INTRAVITREAL INJECTION ENDOPHTHALMITIS RATE AT A SINGLE TERTIARY ACADEMIC CENTER"],"prefix":"10.1097","volume":"44","author":[{"given":"Rachana","family":"Haliyur","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina K.","family":"Sinha","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan;"},{"name":"University of Missouri Kansas City School of Medicine, Kansas City, Missouri;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris A.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Musch","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan;"},{"name":"Department of Epidemiology, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Conrady","sequence":"additional","affiliation":[{"name":"Departments of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, Nebraska; and"},{"name":"Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Zacks","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0490-5054","authenticated-orcid":false,"given":"Michael J.","family":"Huvard","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, Michigan;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"New Engl J Med"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration A randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12348-015-0069-5","article-title":"Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms","volume":"6","author":"Sachdeva","year":"2016","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.ophtha.2011.02.034","article-title":"Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"118","author":"Shah","year":"2011","journal-title":"Ophthalmology"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3928\/23258160-20180501-04","article-title":"Endophthalmitis associated with intravitreal injections of anti-VEGF agents at a tertiary referral center: in-house and referred cases","volume":"49","author":"Yannuzzi","year":"2018","journal-title":"Ophthalmic Surg lasers Imaging Ret"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/IAE.0b013e3182807659","article-title":"Pars plana vitrectomy in the management of patients diagnosed with endophthalmitis following intravitreal anti-vascular endothelial growth factor injection","volume":"33","author":"Chaudhary","year":"2013","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ajo.2018.11.023","article-title":"The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab","volume":"199","author":"Storey","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s00417-022-05607-8","article-title":"Preventive factors, diagnosis, and management of injection-related endophthalmitis: a literature review","volume":"260","author":"Singh","year":"2022","journal-title":"Graefes Archive Clin Exp Ophthalmol"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s40135-019-00208-x","article-title":"Endophthalmitis following intravitreal injections performed in the office versus operating room setting","volume":"7","author":"Uhr","year":"2019","journal-title":"Curr Ophthalmol Rep"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2013.08.037","article-title":"The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection","volume":"121","author":"Storey","year":"2014","journal-title":"Ophthalmology"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1001\/archophthalmol.2011.227","article-title":"Bacterial dispersal associated with speech in the setting of intravitreous injections","volume":"129","author":"Wen","year":"2011","journal-title":"Arch Ophthalmol (Chicago, Ill, 1960)"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3928\/23258160-20151027-07","article-title":"Effect of a strict \u2018No-talking\u2019 policy during intravitreal injection on post-injection endophthalmitis","volume":"46","author":"Garg","year":"2015","journal-title":"Ophthalmic Surg lasers Imaging Retin"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/IAE.0000000000000399","article-title":"Intravitreal injection technique and monitoring: updated guidelines of an expert panel","volume":"34","author":"Avery","year":"2014","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2020.08.013","article-title":"The impact of physician face mask use on endophthalmitis after intravitreal anti\u2013vascular endothelial growth factor injections","volume":"222","author":"Patel","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R16-20250605","first-page":"473","article-title":"Reducing oral flora contamination of intravitreal injections with face mask or silence","volume":"32","author":"Doshi","year":"2012","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jcjo.2021.06.015","article-title":"Impact of patient face mask use on endophthalmitis after intravitreal anti-VEGF injections","volume":"57","author":"H\u00e9bert","year":"2022","journal-title":"Can J Ophthalmol"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1111\/aos.14945","article-title":"Mask use by patients in the context of COVID\u201019 can increase the risk of postinjection endophthalmitis","volume":"100","author":"Blom","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"e1351","DOI":"10.1111\/aos.15069","article-title":"Patients face masks do not increase the risk of post\u2010injection endophthalmitis","volume":"100","author":"Bisorca\u2010Gassendorf","year":"2022","journal-title":"Acta Ophthalmol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/IAE.0000000000002919","article-title":"Patients wearing face masks during intravitreal injections may be at a higher risk of endophthalmitis","volume":"40","author":"Hadayer","year":"2020","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.oret.2019.03.013","article-title":"Current practice preferences and safety protocols for intravitreal injection of anti\u2013vascular endothelial growth factor agents","volume":"3","author":"Uhr","year":"2019","journal-title":"Ophthalmol Retin"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/j.ophtha.2021.05.010","article-title":"The influence of universal face mask use on endophthalmitis risk after intravitreal anti\u2013vascular endothelial growth factor injections","volume":"128","author":"Patel","year":"2021","journal-title":"Ophthalmology"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/IAE.0000000000003193","article-title":"Endophthalmitis after intravitreal injections during the COVID-19 pandemic with implementation of universal masking","volume":"41","author":"Naguib","year":"2021","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1007\/s00417-022-05726-2","article-title":"Post-intravitreal injection endophthalmitis pattern during the COVID-19 pandemic with implementation of patients' masking","volume":"260","author":"Mirghorbani","year":"2022","journal-title":"Graefes Archive Clin Exp Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"e2014564118","DOI":"10.1073\/pnas.2014564118","article-title":"An evidence review of face masks against COVID-19","volume":"118","author":"Howard","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcrs.2004.01.014","article-title":"Visual acuity measurements","volume":"30","author":"Holladay","year":"2004","journal-title":"J Cataract Refract Surg"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies","volume":"31","author":"Mccannel","year":"2011","journal-title":"Retina (Philadelphia, Pa.)"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ajo.2020.10.017","article-title":"Bacterial dispersion associated with various patient face mask designs during simulated intravitreal injections","volume":"223","author":"Patel","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.ophtha.2021.01.007","article-title":"Face masks and bacterial dispersion toward the periocular area","volume":"128","author":"Raevis","year":"2021","journal-title":"Ophthalmology"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:01:27Z","timestamp":1749142887000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004043","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}